<DOC>
	<DOCNO>NCT02984852</DOCNO>
	<brief_summary>The purpose study evaluate single-dose pharmacokinetics relative bioavailability Darunavir ( DRV ) 800 milligram ( mg ) , Cobicistat ( COBI ) 150 mg , Emtricitabine ( FTC ) 200 mg , tenofovir alafenamide ( TAF ) 10 mg administer fixed-dose combination ( FDC ) ( D/C/F/TAF ) tablet healthy adult participant give Treatment A ( reference ) : single dose D/C/F/TAF ( 800/150/200/10 mg ) FDC tablet swallow whole , intact tablet 240milliliter ( mL ) noncarbonated water.Treatment B ( test ) : single dose D/C/F/TAF ( 800/150/200/10 mg ) FDC tablet split tablet swallow 240 mL noncarbonated water . Treatment C ( test ) : single dose D/C/F/TAF ( 800/150/200/10 mg ) FDC tablet crush tablet mixed 4 ounce ( oz ) applesauce .</brief_summary>
	<brief_title>Study Evaluate Relative Bioavailability Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide ( D/C/F/TAF ) Whole Tablet , Split Tablet , Crushed Tablet Healthy Adult Participants</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Nonsmoker least 3 month prior selection Body mass index ( BMI ) 18.0 32 kilogram per square meter ( kg/m^2 ) , inclusive Woman must negative highly sensitive serum ( betahuman chorionic gonadotropin [ betahCG ] ) pregnancy test screen negative sensitive urine pregnancy test Day 1 first dose study drug Woman must agree donate egg ( ovum , oocytes ) purpose assist reproduction study least 90 day receive last dose study drug During study minimum 1 spermatogenesis cycle ( define approximately 90 day ) receive last dose study drug , nonvasectomized man sexually active woman childbearing potential must agree use highly effective barrier method contraception Positive human immunodeficiency virus 1 ( HIV1 ) HIV2 test screen Hepatitis A , B , C infection , confirm positive hepatitis A antibody immunoglobulin M ( IgM ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) test , respectively , screen History renal insufficiency History significant druginduced skin reaction ( , limit , StevensJohnson syndrome ( SJS ) , toxic epidermal necrolysis ( TEN ) , and/or erythema multiforme ) history allergy drug ( , limit , sulfonamide penicillin ) Previously participate multipledose study Darunavir ( DRV ) , Cobicistat ( COBI ) , Emtricitabine ( FTC ) , Tenofovir Alafenamide ( TAF ) , Tenofovir Disoproxil Fumarate ( TDF )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>